source
- J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolioJohnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
- CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in studyCG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…